Similar articles

• Upward trend in financing continues, but fewer feel flush.

  Lawrence S. Lawrence S. Nat Biotechnol. 2007 Jan;25(1):3. doi: 10.1038/nbt0107-3. Epub 2007 Jan 5. Nat Biotechnol. 2007. PMID: 17211374 No abstract available.
• Biotech financing retrenches in Q2.

  Lawrence S. Lawrence S. Nat Biotechnol. 2006 Aug;24(8):883. doi: 10.1038/nbt0806-883. Epub 2006 Aug 3. Nat Biotechnol. 2006. PMID: 16900116 No abstract available.
• Beyond the crunch.

  [No authors listed] [No authors listed] Nat Rev Drug Discov. 2009 Jan;8(1):3. doi: 10.1038/nrd2802. Nat Rev Drug Discov. 2009. PMID: 19123266 No abstract available.
• A change in the market--investing in diagnostics.

  Batchelder K, Miller P. Batchelder K, et al. Nat Biotechnol. 2006 Aug;24(8):922-6. doi: 10.1038/nbt0806-922. Nat Biotechnol. 2006. PMID: 16900131 Review. No abstract available.
• Aftermarket performance of initial public offerings for health care firms.

  Hughes DW, Reinhart WJ. Hughes DW, et al. J Ambul Care Mark. 1992;5(1):185-96. J Ambul Care Mark. 1992. PMID: 10122751 Review. No abstract available.